The PHARM Connect Congress 2011

9-10 February 2011, Budapest, Hungary.
The PHARM Connect Congress 2011, an event organised by The Events Group, offers the perfect setting for solution providers to present their products and services directly to key decision makers of target client population throughout Central & Eastern Europe.

Strictly operating on an invitation only basis guarantees that the highest level of delegation is present. Each solution provider at the PHARM Connect Congress is selected based on requirements and interests provided by attending Pharmaceutical professionals prior to the Congress event.

Over two days, service providers will meet and interact with the leading director and C level practitioners through a number of pre-arranged one-to-one business meetings and other networking activities.

Several weeks in advance of the Congress, the TEG Meeting Scheduler is made available to all solution providers and delegates attending. Participants receive individualized passwords to access the website where they are able to select key presentations, pre-schedule one-to-one meetings and confirm their presence at several additional networking activities. Through the Meeting Scheduler, attendees have the opportunity to create their own itinerary prior to the Congress taking place.

This networking event presents a unique opportunity to develop meaningful and valuable business relations.

For further information and registration, please visit:
http://www.pharmconnect.eu

About The Events Group
The Events Group is one of Europe's leading business information providers. With two main areas of focus, business-to-business Congresses and Professional Training, we primarily operate within key emerging markets: Central & Eastern Europe.

Our unique business-to-business Congresses bring together senior-level executives from Europe’s largest organisations with a select and diversified group of leading edge sponsors. Strictly operating on an invitation only basis guarantees that the highest level of delegation is present.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Roche and Ignyta reach definitive merger agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta ...

Antidepressant may help combat the course of multi…

The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remi...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

FDA updates the label of Tasigna to reflect that c…

The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinu...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]